• 1
    Castellino FJ, Ploplis VA. Human plasminogen: structure, activation, and function. In: WaismanDM, ed. Plasminogen Structure, Activation, and Regulation. New York, NY: Kluwer Academic/Plenum Publishers, 2003: 317.
  • 2
    Sodeinde OA, Subrahmanyam YV, Stark K, Quan T, Bao Y, Goguen JD. A surface protease and the invasive character of plague. Science 1992; 258: 10047.
  • 3
    Schott D, Dempfle CE, Beck P, Liermann A, Mohr-Pennert A, Goldner M, Mehlem P, Azuma H, Schuster V, Mingers AM, Schwarz HP, Kramer MD. Therapy with a purified plasminogen concentrate in an infant with ligneous conjunctivitis and homozygous plasminogen deficiency. N Engl J Med 1998; 339: 167986.
  • 4
    Drew AF, Kaufman AH, Kombrinck KW, Danton MJS, Daugherty CC, Degen JL, Bugge TH. Ligneous conjunctivitis in plasminogen-deficient mice. Blood 1998; 91: 161624.
  • 5
    Atkinson SJ, Ward RV, Reynolds JJ, Murphy G. Cell-mediated degradation of type IV collagen and gelatin films is dependent on the activation of matrix metalloproteinases. Biochem J 1992; 288 (Pt 2): 60511.
  • 6
    Murphy G, Atkinson S, Ward R, Gavrilovic J, Reynolds JJ. The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann NY Acad Sci 1992; 667: 112.
  • 7
    Campbell PG, Andress DL. Plasmin degradation of insulin-like growth factor-binding protein-5 (IGFBP-5): regulation by IGFBP-5-(201-218). Am J Physiol 1997; 273: E9961004.
  • 8
    Rifkin DB, Mazzieri R, Munger JS, Noguera I, Sung J. Proteolytic control of growth factor availability. APMIS 1999; 107: 805.
  • 9
    Heinz HP, Loos M. Activation of the first component of complement, C1: comparison of the effect of sixteen different enzymes on serum C1. Immunobiology 1983; 165: 17585.
  • 10
    Miles LA, Hawley SB, Baik N, Andronicos NM, Castellino FJ, Parmer RJ. Plasminogen receptors: the sine qua non of cell surface plasminogen activation. Front Biosci 2005; 10: 175462.
  • 11
    Ranson M, Andronicos NM, O’Mullane MJ, Baker MS. Increased plasminogen binding is associated with metastatic breast cancer cells: differential expression of plasminogen binding proteins. Br J Cancer 1998; 77: 158697.
  • 12
    Ullberg M, Kronvall G, Wiman B. New receptor for human plasminogen on gram positive cocci. APMIS 1989; 97: 9961002.
  • 13
    Ullberg M, Kronvall G, Karlsson I, Wiman B. Receptors for human plasminogen on gram-negative bacteria. Infect Immun 1990; 58: 215.
  • 14
    Miles LA, Dahlberg CM, Plescia J, Felez J, Kato K, Plow EF. Role of cell-surface lysines in plasminogen binding to cells: identification of a-enolase as a candidate plasminogen receptor. Biochemistry 1991; 30: 168291.
  • 15
    Hajjar KA, Jacovina AT, Chacko J. An endothelial cell receptor for plasminogen tissue plasminogen activator. 1. Identity with annexin II. J Biol Chem 1994; 269: 211917.
  • 16
    Wistedt AC, Kotarsky H, Marti D, Ringdahl U, Castellino FJ, Schaller J, Sjobring U. Kringle 2 mediates high affinity binding of plasminogen to an internal sequence in streptococcal surface protein PAM. J Biol Chem 1998; 273: 244204.
  • 17
    Rios-Steiner JL, Schenone M, Mochalkin I, Tulinsky A, Castellino FJ. Structure and binding determinants of the recombinant kringle-2 domain of human plasminogen to an internal peptide from a group A Streptococcal surface protein. J Mol Biol 2001; 308: 70519.
  • 18
    Bugge TH, Lund LR, Kombrinck KK, Nielsen BS, Holmback K, Drew AF, Flick MJ, Witte DP, Dano K, Degen JL. Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene 1998; 16: 3097104.
  • 19
    Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 2731.
  • 20
    Bugge TH, Flick MJ, Daugherty CC, Degen JL. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 1995; 9: 794807.
  • 21
    Ploplis VA, Carmeliet P, Vazirzadeh S, Van Vlaenderen I, Moons L, Plow EF, Collen D. Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation 1995; 92: 258593.
  • 22
    Castellino FJ, Ploplis VA. Structure and function of the plasminogen/plasmin system. Thromb Haemost 2005; 93: 64754.
  • 23
    Bugge TH, Kombrinck KW, Flick MJ, Daugherty CC, Danton MJ, Degen JL. Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Cell 1996; 87: 70919.
  • 24
    Warming S, Costantino N, Court DL, Jenkins NA, Copeland NG. Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res 2005; 33: e36.
  • 25
    Yanagawa Y, Kobayashi T, Ohnishi M, Kobayashi T, Tamura S, Tsuzuki T, Sanbo M, Yagi T, Tashiro F, Miyazaki J. Enrichment and efficient screening of ES cells containing a targeted mutation: the use of DT-A gene with the polyadenylation signal as a negative selection maker. Transgenic Res 1999; 8: 21521.
  • 26
    Lijnen HR, Van Hoef B, De Coek F, Okada K, Ueshima S, Matsuo O, Collen D. On the mechanism of fibrin-specific plasminogen activation by staphylokinase. J Biol Chem 1991; 266: 1182632.
  • 27
    Horrevoets AJG, Pannekoek H, Nesheim ME. Production and characterization of recombinant human plasminogen(S741C-Fluorescein). A novel approach to study zymogen activation without generation of active protease. J Biol Chem 1997; 272: 217682.